BRPI0620800A2 - uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido - Google Patents

uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido

Info

Publication number
BRPI0620800A2
BRPI0620800A2 BRPI0620800A BRPI0620800A BRPI0620800A2 BR PI0620800 A2 BRPI0620800 A2 BR PI0620800A2 BR PI0620800 A BRPI0620800 A BR PI0620800A BR PI0620800 A BRPI0620800 A BR PI0620800A BR PI0620800 A2 BRPI0620800 A2 BR PI0620800A2
Authority
BR
Brazil
Prior art keywords
nanoparticles
protein
matrix
embedded
active agent
Prior art date
Application number
BRPI0620800A
Other languages
English (en)
Inventor
Jindrich Cinatl
Jörg Kreuter
Klaus Langer
Martin Michaelis
Sebastian Dreis
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of BRPI0620800A2 publication Critical patent/BRPI0620800A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0620800A 2005-12-27 2006-12-22 uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido BRPI0620800A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005062440A DE102005062440B4 (de) 2005-12-27 2005-12-27 Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
PCT/EP2006/012524 WO2007073932A2 (de) 2005-12-27 2006-12-22 Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen

Publications (1)

Publication Number Publication Date
BRPI0620800A2 true BRPI0620800A2 (pt) 2016-11-01

Family

ID=38110688

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620800A BRPI0620800A2 (pt) 2005-12-27 2006-12-22 uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido

Country Status (14)

Country Link
US (1) US20090181090A1 (pt)
EP (1) EP1965769A2 (pt)
JP (1) JP2009521515A (pt)
KR (1) KR20080081080A (pt)
CN (1) CN101346131A (pt)
AU (1) AU2006331030A1 (pt)
BR (1) BRPI0620800A2 (pt)
CA (1) CA2631003A1 (pt)
DE (1) DE102005062440B4 (pt)
IL (1) IL192343A0 (pt)
NZ (1) NZ569898A (pt)
RU (1) RU2404916C2 (pt)
WO (1) WO2007073932A2 (pt)
ZA (1) ZA200804572B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811175D0 (en) * 2008-06-18 2008-07-23 Prendergast Patrick T Anti-tumour compositions and methods
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US20120263739A1 (en) * 2009-11-13 2012-10-18 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
CN103202812B (zh) * 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
JP6320042B2 (ja) 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
CN102846562B (zh) * 2012-09-28 2014-11-26 山东大学 一种半乳糖介导的冬凌草甲素白蛋白纳米粒及其制备方法
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
CN103275965A (zh) * 2013-05-22 2013-09-04 武汉理工大学 一种自恢复多功能软包埋细胞固载体系及其制备方法
CN103611169A (zh) * 2013-12-02 2014-03-05 东南大学 具有靶向性的免疫磁性白蛋白纳米球及制备方法
AU2015258891A1 (en) * 2014-05-16 2016-12-01 Dana-Farber Cancer Institute, Inc. Protein-based particles for drug delivery
WO2016020697A1 (en) * 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
US20160199497A1 (en) * 2014-09-10 2016-07-14 Purdue Research Foundation Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy
CN104211815B (zh) * 2014-09-12 2017-06-06 华东理工大学 一种铁蛋白重链亚基纳米载药系统及其制备方法与应用
CN104382854A (zh) * 2014-10-09 2015-03-04 唐春林 一种多柔比星脂质微泡及其制备方法
CN104324005A (zh) * 2014-10-09 2015-02-04 唐春林 一种争光霉素脂质微泡及其制备方法
CN104382904B (zh) * 2014-10-09 2018-02-13 唐春林 一种长春新碱脂质微泡及其制备方法
US10265413B2 (en) 2014-11-05 2019-04-23 University Of The Sciences In Philadelphia High molecular weight biodegradable gelatin-doxorubicin conjugate
MA41866A (fr) * 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN105343005A (zh) * 2015-11-06 2016-02-24 中国药科大学 一种新型中药纳米粒口服吸收增强技术
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) * 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CN108741097A (zh) * 2018-05-17 2018-11-06 华南理工大学 一种蛋白自组装包埋难溶活性物质纳米制品及其制备方法
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
CN110051653A (zh) * 2019-06-03 2019-07-26 辽宁大学 一种制备荜茇酰胺白蛋白纳米粒及冻干粉的方法
CN111249254B (zh) * 2020-01-16 2022-02-18 暨南大学 一种包载黄芩苷的叶酸偶联白蛋白纳米粒的制备方法和应用
US20230135752A1 (en) * 2020-03-27 2023-05-04 PhotoQ3 Inc. Medicament for killing tumor cells
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147976T1 (de) * 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
AU4373499A (en) * 1999-06-02 2000-12-28 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
DE102004011776A1 (de) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen

Also Published As

Publication number Publication date
US20090181090A1 (en) 2009-07-16
NZ569898A (en) 2011-06-30
ZA200804572B (en) 2009-03-25
WO2007073932A3 (de) 2007-09-27
RU2404916C2 (ru) 2010-11-27
JP2009521515A (ja) 2009-06-04
DE102005062440A1 (de) 2007-07-05
EP1965769A2 (de) 2008-09-10
DE102005062440B4 (de) 2011-02-24
CA2631003A1 (en) 2007-07-05
CN101346131A (zh) 2009-01-14
KR20080081080A (ko) 2008-09-05
RU2008130167A (ru) 2010-01-27
WO2007073932A2 (de) 2007-07-05
IL192343A0 (en) 2009-02-11
AU2006331030A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
BRPI0620800A2 (pt) uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido
GT200600465A (es) Composición para detergente líquido
BRPI0513847A (pt) formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
CL2008002422A1 (es) Uso de una composicion primaria que comprende un agente que reduce la cantidad de proteobacteria que consiste de polimixina b y neomicina para tratar o prevenir desordenes metabolicos y para mantener el peso corporal total de un sujeto.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
BRPI1010903A2 (pt) partícula modificada na superfície, composição farmacêutica, método para intensificar a absorção celular de um agente ativo, uso de uma pluralidade de partículas modificadas na superfície, e, pluralidade de partículas modificadas na superfície
BRPI0818673A2 (pt) terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2
CY2019042I1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
DE602007001555D1 (de) Fahrzeugaufbaukonstruktion
BRPI0818073A2 (pt) Composição de fluido de tratamento de poço e métodos de uso que incluem uma formulação de percarbonato de liberação retardada
BRPI0613752A2 (pt) agente fungicidamente ativo, kit de 2- componentes, processo para combater fungos nocivos, e, uso do agente
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
FI20055150A (fi) Sakeuden muuttaminen ja mittaaminen
DE502005004599D1 (de) Bremszylinder mit parkbremsfunktion
CL2007002931A1 (es) Agente tensioactivo que comprende un vehiculo lipidico y una combinacion de analogo polipeptidico de la proteina tensioactiva nativa sp-c y sp-b; composicion tensioactiva y composicion farmaceutica que comprenden dicho agente; uso del agente para tra
BRPI0619911A2 (pt) composto, pró-droga, agente farmacêutico, e, uso do composto
BRPI0720160A2 (pt) Liberação de um agente de controle de odor através do uso de um lenço pré-umidecido
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 018080039354 DE 24/06/2008.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 DA RPI NO 2129 DE 25/10/2011 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 - AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 DA RPI NO 2158 DE 15/05/2012 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 - AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]